Should you select monoclonal or polyclonal antibodies for your lateral flow rapid test? Some readers are probably wondering why polyclonal antibodies are not a thing of the past, like manual transmissions on cars and telephone landlines. However, the older models still have many advantages. This blog explores these advantages in the context of lateral flow assays.
As you may know, the core of our mission at DCN is to deliver positive outcomes for our clients and for our broader community. Thanks to your support, this year we have been able to expand our list of charitable contributions to include a variety of organizations.
The selection of the right antibody is key to creating a robust immunoassay that consistently provides reliable analytical information.
DCN Dx and QIAGEN Lake Constance announced today that Rapid Pathogen Screening, Inc. (RPS) was the winner of the first $10,000 Innovation Award at the Advanced Lateral Flow Course. RPS was selected from 38 entrants that described advances in diagnostic technology.
DCN Dx and E25Bio, an MIT-spinoff diagnostics company from the Gehrke Lab at IMES, have announced a partnership for the design, development and manufacture of an innovative new infectious disease testing technology.
Innovative chemistry has developed several antibody labeling materials that can be used to modify antibodies to enhance their detectability. These antibody labeling materials include gold nanoparticles, colored cellulose particles, colored latex particles, magnetic particles, carbon nanoparticles, quantum dots, fluorophores and various enzymes.
DCN Dx has been recognized by Med Tech Outlook Magazine as a top 10 solution provider for in-vitro diagnostic technology for 2018. Read the exclusive article on Brendan O’Farrell, President & Founding Partner of DCN Dx here!
DCN Dx, in collaboration with Qiagen Lake Constance, is pleased to announce the first Rapid Testing Innovation Award, to be presented at the 2018 Advanced Lateral Flow Course in October. This competitive prize includes a cash award of $10,000 and will recognize the best innovation in the field of rapid point-of-care assays or the most novel application for rapid assays during the past year.
A rapid diagnostic test is a tool that, like any other tool, must be designed and built for its intended purpose. Before going into the lab to develop an assay, one must start at the end and correctly identify the goals and use of the product. Only then can point of care diagnostic products be designed correctly.
Registration is open! Join us for this 3-day educational seminar co-hosted by DCN Dx and QIAGEN Lake Constance. The content of this event is aimed at developers and manufacturers of rapid diagnostic tests and their associated products.